Your trusted source for investing success
Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.
Click here to get your free report!Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.
22nd Century Group announced in cooperation with the University of Virginia it had completed a harvest of hemp plants and potentially found hemp varieties for commercial production.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Here is a look at 5 stocks searching for novel therapies in the quest for the growing population in the anti-aging market.
ProMIS Neurosciences provided an update from a preclinical study comparing PMN310 to other amyloid beta-directed antibodies combating Alzheimer’s disease.
Gilead Sciences shared the promotion of Dr. Alessandro Riva to executive vice president of Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs.
With a few months left to go in 2017, here the Investing News Network (INN) looks at the 4 top pharma stocks on the NASDAQ year-to-date.
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
By Jocelyn Aspa
Pieris Pharmaceuticals (NASDAQ:PIRS) has announced that it has appointed Ingmar Bruns, M.D., Ph..D as vice president of clinical development.
As quoted in the press release:
Dr. Bruns is an accomplished physician and brings to Pieris a wealth of oncology and hematology experience, a deep science background, and a strong clinical development acumen.
“We
By Jocelyn Aspa
Realm Therapeutics plc (AIM: RLM) has announced the private placement of $26 million, previously disclosed September 21, was approved by its shareholders at a general meeting in London on October 9.
As quoted in the press release:
The 66,396,485 new ordinary shares issued by the Company in the PIPE were admitted to
By Shelly Kumar
CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Harvest One Cannabis Inc.(TSXV:HVST) tremendous progress in growing its international footprint. The company’s wholly-owned United Greeneries subsidiary is awaiting approval from Health Canada for its ACMPR license to sell, but its
By Jocelyn Aspa
Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) has announced positive initial results from its research product with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
As quoted in the press release:
The research project evaluated tannin-chitosan (TNN-CHT) based hydrogel formulations in combination with synthetic cannabidiol (CBD) in an anti-inflammatory preclinical
Bluebee, a company driving genomic data-driven medicine, and Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read sequencing, announced they have integrated the PacBio® de novo assembly pipeline onto the Bluebee® genomics analysis platform. The integration creates a simplified workflow and fully automated, end-to-end data analysis solution that allows
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
By Shelly Kumar
Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”) announced today that it has entered into a Collaboration and Licensing Agreement (the “Agreement”) with Canntab Therapeutics Limited (“Canntab”) of Toronto. Canntab has developed a patent-pending oral sustained release formulation for cannabinoids (the “Sustained Release Product” or the “Product”). Under the Agreement,
By Shelly Kumar
Harvest One Cannabis Inc.(TSXV:HVST) is pleased to provide a market update on its wholly owned subsidiary, Satipharm AG (“Satipharm”):
Satipharm has received German “Free Sales Certificate” reducing constraints for international export
Australian Regulatory Authority has issued final approval for CBD capsule prescription in Australia
Strong increase in European dietary supplement
By Jocelyn Aspa
Revive Therapeutics (TSXV:RVV) has announced that it has entered into a research collaboration with Sanyal Biotechnology focused on advancing cannabinoids for treatment of liver diseases.
As quoted in the press release:
The collaboration will initially focus on the use of cannabidiol on a novel autoimmune hepatitis (AIH) model based on the DIAMOND™
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
VistaGen Therapeutics received a notice from the US Patent and Trademark Office regarding the certain methods of production for AV-101.
Avenue Therapeutics, a Fortress Biotech company, announced the first patient dosed in their phase 3 clinical trial of intravenous tramadol for the management of moderate to moderately severe pain in patients following bunionectomy surgery.
